secwatch.observer — SEC 8-K summary
======================================

Issuer:     CATALYST PHARMACEUTICALS, INC. (CPRX)
CIK:        0001369568
Form:       8-K
Filed at:   2023-07-21T23:59:59+00:00
Accession:  0001193125-23-191394
Event type: m_and_a
Sentiment:  positive
Materiality: 0.75
Item codes: 2.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Catalyst completes $75M license for vamorolone, a DMD drug with PDUFA Oct 26, 2023
--------------------------------------------------------------------------------

- All-cash $75M license payment plus $15M equity investment for 11.26% stake in Santhera.
- Vamorolone has FDA Fast Track and Orphan Drug status; PDUFA action date Oct 26, 2023.
- Catalyst expects to launch vamorolone in the U.S. early Q1 2024, if approved.
- Minimal sales force expansion (<10 new reps) due to synergy with existing neuromuscular franchise.
- Catalyst will pay milestones and royalties on net sales; vamorolone rights cover U.S., Canada, Mexico.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523191394/0001193125-23-191394-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1369568/000119312523191394/d419142d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-191394

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer